Zonghai Li, M.D., Ph.D.,Associate Professor
Principal Investigator: Cancer BioTherapy Unit
Email: Zonghaili@shsci.org
Tel: 86-21-64436601
Fax: 86-21-64432027


Education
2002-2005: M.D. in Pathogenic Biology, Fudan University, Shanghai, China
1997-2000: Master in Pathophysiology, Central South University, Changsha, China
1992-1997: Bachelor in Medicine, Hunan Medical University, Changsha, China

Experience
2005-present: Associate Professor & Principal Investigator, National Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute.
2000-2002: Project manager, Guilin Pavay Gene Pharmaceutical Inc.

Professional Affiliations
Member, International society for cell and gene therapy of cancer.

Yuhong Xu, Ph.D., Professor
Principal Investigator: Cancer BioTherapy Unit
Email：yhxu@sjtu.edu.cn

Team member

Research areas:
The overall aim of the research carried out in our lab is to develop targeting drugs for cancer therapy and identify novel biomarkers for cancer diagnosis.

Research Area 1---Identify antibodies or peptide ligands against tyrosine kinase receptors. Drugs targeting against tyrosine kinase receptors become important agents for cancer therapy. One of our interests is to identify some antibodies or peptide ligands against receptor over-expressed in cancer or mutant receptor expressed only in cancer. We are now making some monoclonal antibodies against EGFRvIII (a mutant form of EGFR), IGF-1R and Tie-2. Using phage display, we have identified novel peptide ligands for EGFR and Tie 2. Recently, we have developed a novel phage display method (Shi B, BioTechniques, 2007). Using this method, we have identified some scFv antibodies against EGFR and EGFRvIII. Currently, we are 1) to genetic engineering the antibodies against EGFRvIII; 2) to determine the anti-tumor effect of the antibodies; 3) to make immunotoxin against EGFR and EGFRvIII; 4) to radiolabel these antibodies for caner diagnosis and therapy.

Research Area 2---Develop receptor-targeting nanoparticle and liposome
Receptor-targeting nanoparticle and liposome are promising vectors for delivering drug into cancer cells. On the basis of those antibodies and peptides identified by us, we are now trying to make targeting nanoparticle and liposome. Nanoparticles are made by displaying peptide ligands on viral capsid particles derived from HBsAg. Immunoliposome are also being made by conjugate antibody fragments to liposome. The immunoliposome was used to carry chemical drugs and therapeutic genes for killing cancer cells.

Research Area 3---Develop Cancer Vaccine
Cancer vaccine has become a promising way to kill cancer. We are now using DC vaccine and peptide vaccine to kill some kind of solid tumor.

Research Area 4---Develop autoantibody profiling for the cancer diagnosis and therapy.
Cancer early diagnosis is critical for the prognosis. However, the tumor associated antigen was minimal in early stage cancer patient. The method available now is not sensitive enough to detect these minimal tumor associated antigen. Since, minimal antigen can induce lots of antibody, we are now trying to develop autoantibody profiling in the cancer patient.

Recent Publications：
1.  Zonghai Li, Ruijiao Zhao, Xianghua Wu, Ye Sun, Ming Yao, Jinjun Li, Yuhong Xu*, Jianren Gu*. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J; 2005;19（14）：1978-1985 ,
2.  Zonghai Li，Jie Zhang，Ruijiao Zhao，Yuhong Xu* and Jianren Gu*. Preparation of peptide-targeted phagemid particles using protein III modified helper phage. BioTechniques. 2005;39(4): 493-496.
3.  Liang, Y., Shi, B., Zhang, J., Jiang, H., Xu, Y., Li, Z*. and Gu, J*. Better Gene Expression by (-)Gene than by (+)Gene in phage gene delivery systems. Biotechnology Progress. 2006 May-Jun;22(3):626-30.
4.  *Zonghai Li*, Hua Jiang, Jie Zhang, *Jianren Gu，Cell targeted phagemid particles preparation using E.coli bearing ligand-pIII encoding helper phage genome，BioTechniques, 2006，41（6）：706-707.
5.  Hua Jiang, Jie Zhang, Bizhi Shi, Yuhong Xu, Zonghai Li*, Jianren Gu *， Application of EGFP-EGF Fusions to Explore the Mechanism of Endocytosis of Epidermal Growth Factor Receptor， Acta Pharmacol Sin. 2007 Jan;28(1):111-7
6.  Bizhi Shi, Huamao Wang, Shengrong Guo, Yuhong Xu, Zonghai Li*, Jianren Gu*， Protein III-based single-chain antibody phage display using bacterial cells bearing an additional genome of a gene-III-lacking helper phage. BioTechniques, 2007：42（6）756-9
7.  Wu X, Zhao R, Li Zonghai, Ming Yao, Huamao Wang, Junsong Han, Shumin Qu, Xianlian Chen, Lianfang Qian, Ye Sun, Yuhong Xu, and Jianren Gu. A novel small peptide as a targeting ligand for receptor tyrosine kinase Tie2. Biochem Biophys Res Co. 2004，315(4):1004-10.
8.  Shuiliang Wang, FeLan, Li Huang, Li Dong, Zh Zhu, Zonghai Li , You Xie，Ji Fu. Suppression of hLRH-1 mediated by a DNA vector-based RNA interference results in cell cycle arrest and induction of apoptosis in hepatocellular carcinoma cell BEL-7402. Biochem and Biophy Res Co. 2005, 333: 917-924
9.  Yaqiong Zhang, Shengrong Guo, Chengfei Lu, Li Liu, Zonghai Li, Jianren Gu, Poly (ε-caprolactone)-b-Poly (ethylene glycol)-b-Poly (ε-caprolactone) Triblock Copolymers：Synthesis and Self-Assembly in Aqueous Solutions, Journal of Polymer Science Part A: Polymer Chemistry, 2007，45（4）：605-13.
10.  Na Zhang, Shengrong Guo, Huiqin Li, Li Liu, Zonghai Li, Jianren Gu, Synthesis of Three Types of Amphiphilic Poly(ethylene glycol)-block-Poly(sebacic anhydride) Copolymers and Studies of their Micellar Solutions, Macromolecular Chemistry and Physics, 207(2006) 1359-1367.
11.  Chengfei LU, Shengrong GUO, Li Liu, Yaqiong ZHANG, Zonghai LI, Jianren GU Aggregation Behavior of MPEG-PCL Diblock Copolymers in Aqueous Solutions. Journal of Polymer Science Part B: Polymer Physics, 2006. 44，3406-3417
12.  Jiang Hua, Xiumei Cai, Bizhi Shi,Jie Zhang, Zonghai Li*, Jianren Gu，Development of efficient RNA interference system using EGF-displaying phagemid particles. Acta Pharmacol Sin. 2008, In press.
13.  Guo Y，Sun Y，Gu J，Xu Y *. Capillary electrophoresis analysis of poly(ethylene glycol) and ligand-modified polylysine gene delivery vectors. ，Analytical Biochemistry, 2007, 363(2): 204-9
Note: * Corresponding author